Treatment applied to COVID-19 patients in Puebla that reduced 48% mortality to be tested at Harvard
The Harvard University, in the United States, will test a treatment developed by Mexican specialists to serve the COVID-19[feminine[feminine.
The multicentre work will be led by Ari Moskowitz, Assistant Professor of Medicine Beth Israel Deaconess Medical Center the Harvard.
The scientist Sigifredo Pedraza Sánchez, of the Faculty of Sciences of ONE, explained that the Mexican treatment is to mix prednisone Yes cyclosporine A.
The pilot study was conducted in 209 COVID-19 patients admitted to the regional hospital del ISSSTE of Puebla. Their results, published in the Journal of Internal Medicine, showed an improvement in the clinical outcome of patients with moderate to severe illnessand a 48 percent reduction in mortality.
The steroids prednisone or prednisolone have been used, drugs known since the 1950s that reduce the inflammatory response during the immune response and help patients recover when the inflammatory response is very strong in different types of diseases, ”said Pedraza. Sanchez.
The cyclosporine A, detailed the university scientist, it is used mainly in patients who have undergone a kidney transplant having immunosuppressive properties. It is also used in autoimmune diseases to reduce the inflammatory response.
The study was carried out between April and May 2020, under the direction of the internist Jose Luis Galvez Romero of ISSSTE Puebla. He had the participation of the mathematician Oscar Palmeros Rojas from the Autonomous University of Chapingo (UACh), and the biologist in science, Sigifredo Pedraza Sánchez.
209 patients hospitalized at ISSSTE Puebla were analyzed. Of these, 104 received only prednisone or prednisolone, while 105 received this steroid with cyclosporine A. Each patient was followed for 28 days and their progress, clinical results and s’ there was an improvement or a decrease in mortality were analyzed, ”added Pedraza.
The treatment lasted ten days in the hospital. Among the results, it appears that the control group (to which only prednisone was applied) had a mortality of 35%, while in the second case (with prednisone and cyclosporin A) it was reduced to 22%.
The patient group consisted of people with COVID-19 in the moderate, severe and mild phase; the positive effects of the pharmacological strategy were better in people with moderate to severe disease.
When these groups with moderate to severe disease were compared, mortality in the group that received steroids only was 48.5 percent, while the group that added cyclosporin A was 24 percent. hundred, ”he said.
With information from López-Dóriga Digital
–
